Multiple myeloma (MM) is composed of an array of multiple clones, each potentially associated with different clinical behavior. Previous studies focused on clinical implication of centrosome amplification (CA) in MM show contradictory results. It seems that the role of CA as well as CA formation in MM differ from other malignancies. This has brought about a question about the role of CA positive clone which is--is it going to be a more aggressive clone evolutionally arising under pressure of negative conditions or can CA serve as a marker of cell abnormality and lead to cell death and further elimination of this damaged subpopulation? This current review is devoted to the discussion of the existence of MM subclones with centrosome amplification (CA), its evolutionary behaviour within intraclonal heterogeneity as well as its potential impact on the disease progression and MM treatment.

Department of Haematooncology Faculty of Medicine University of Ostrava Czech Republic

Department of Haematooncology University Hospital Ostrava Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc17000857

003      

CZ-PrNML

005      

20170116101221.0

007      

ta

008      

170103s2016 ne f 000 0|eng||

009      

AR

024    7_

$a 10.1016/j.critrevonc.2015.10.019 $2 doi

024    7_

$a 10.1016/j.critrevonc.2015.10.019 $2 doi

035    __

$a (PubMed)26589397

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a ne

100    1_

$a Kryukova, Elena $u Department of Haematooncology, Faculty of Medicine, University of Ostrava, Czech Republic; Department of Haematooncology, University Hospital Ostrava, Czech Republic.

245    10

$a Centrosome amplification and clonal evolution in multiple myeloma: Short review / $c E. Kryukova, F. Kryukov, R. Hajek,

520    9_

$a Multiple myeloma (MM) is composed of an array of multiple clones, each potentially associated with different clinical behavior. Previous studies focused on clinical implication of centrosome amplification (CA) in MM show contradictory results. It seems that the role of CA as well as CA formation in MM differ from other malignancies. This has brought about a question about the role of CA positive clone which is--is it going to be a more aggressive clone evolutionally arising under pressure of negative conditions or can CA serve as a marker of cell abnormality and lead to cell death and further elimination of this damaged subpopulation? This current review is devoted to the discussion of the existence of MM subclones with centrosome amplification (CA), its evolutionary behaviour within intraclonal heterogeneity as well as its potential impact on the disease progression and MM treatment.

650    _2

$a apoptóza $x fyziologie $7 D017209

650    _2

$a karcinogeneze $x patologie $7 D063646

650    _2

$a proliferace buněk $7 D049109

650    _2

$a centrozom $x patologie $7 D018385

650    _2

$a klonální evoluce $x fyziologie $7 D060965

650    _2

$a buněčné klony $7 D002999

650    _2

$a progrese nemoci $7 D018450

650    _2

$a lidé $7 D006801

650    _2

$a mnohočetný myelom $x genetika $x patologie $7 D009101

650    _2

$a fyziologický stres $x fyziologie $7 D013312

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

655    _2

$a přehledy $7 D016454

700    1_

$a Kryukov, Fedor $u Department of Haematooncology, Faculty of Medicine, University of Ostrava, Czech Republic; Department of Haematooncology, University Hospital Ostrava, Czech Republic. Electronic address: f.kryukov@gmail.com.

700    1_

$a Hajek, Roman $u Department of Haematooncology, Faculty of Medicine, University of Ostrava, Czech Republic; Department of Haematooncology, University Hospital Ostrava, Czech Republic.

773    0_

$w MED00005043 $t Critical reviews in oncology/hematology $x 1879-0461 $g Roč. 98, č. - (2016), s. 116-21

856    41

$u https://pubmed.ncbi.nlm.nih.gov/26589397 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20170103 $b ABA008

991    __

$a 20170116101325 $b ABA008

999    __

$a ok $b bmc $g 1179997 $s 961424

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2016 $b 98 $c - $d 116-21 $e 20151102 $i 1879-0461 $m Critical reviews in oncology/hematology $n Crit Rev Oncol Hematol $x MED00005043

GRA    __

$a NV15-29667A $p MZ0

LZP    __

$a Pubmed-20170103